Clarity from
the first conversation.

A U.S. healthcare holding company focused on acquiring, integrating, and expanding specialized apheresis clinics. The platform is in development.

The earlier Angeliki Fund website described a private equity fund focused on dementia and aging-related care. Angeliki’s current strategy is a holding company focused specifically on U.S. apheresis clinic businesses.

This website presents the platform-development strategy. It does not list an operating clinic network or announce completed acquisitions.

No investment subscription or public offering is available here. This is a corporate website for information about the company, acquisitions, and potential healthcare partnerships.

Established U.S. businesses with a meaningful therapeutic apheresis focus, clear operating foundations, and a potential fit with Angeliki’s integration strategy. Plasma donation centers are outside the current focus.

California and Florida are the initial acquisition priorities, with Texas also of interest. These priorities do not represent current clinic locations.

Financial and operating requirements are evaluated during an acquisition discussion. We do not publish valuation multiples, financing terms, or transaction commitments on this website.

Please keep the first introduction non-confidential. Before sharing sensitive business information, discuss appropriate confidentiality arrangements with the team.

No. It provides corporate information and a way to contact Angeliki about business matters. Patients should contact their treating clinicians about medical care.

Use the healthcare partnership contact option to introduce your organization and the topic you would like to discuss. Do not include patient information.

We are retaining the existing business contact address during the brand transition. The company strategy described here is Angeliki Apheresis.